WallStSmart

Hubbell Inc (HUBB)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Hubbell Inc generates 86% more annual revenue ($6.00B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 15.1%. HUBB appears more attractively valued with a PEG of 2.38. WST earns a higher WallStSmart Score of 65/100 (C+).

HUBB

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 4.0Quality: 5.5
Piotroski: 4/9

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HUBBSignificantly Overvalued (-68.2%)

Margin of Safety

-68.2%

Fair Value

$306.75

Current Price

$490.16

$183.41 premium

UndervaluedFair: $306.75Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$322.30

$136.35 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HUBB1 strengths · Avg: 9.0/10
Return on EquityProfitability
25.8%9/10

Every $100 of equity generates 26 in profit

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

HUBB2 concerns · Avg: 4.0/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

P/E RatioValuation
29.0x4/10

Moderate valuation

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.142/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : HUBB

The strongest argument for HUBB centers on Return on Equity. Profitability is solid with margins at 15.1% and operating margin at 17.7%. Revenue growth of 11.1% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : HUBB

The primary concerns for HUBB are PEG Ratio, P/E Ratio.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

HUBB profiles as a mature stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.17 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (65/100 vs 62/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hubbell Inc

INDUSTRIALS · ELECTRICAL EQUIPMENT & PARTS · USA

Hubbell Incorporated designs, manufactures, and sells electrical and electronic products in the United States and internationally. The company is headquartered in Shelton, Connecticut.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?